US SEC and DoJ investigating SciClone activities abroad
This article was originally published in Scrip
Executive Summary
SciClone Pharmaceuticals, the US-based speciality drug company with a particular focus on the Chinese market, is under investigation by both the US Securities and Exchange Commission and the US Department of Justice over its activities in China and other foreign countries.